Seragene Therapeutics

SeraGene has developed SG-001, a universal siRNA-based hemostatic agent aimed at treating a wide range of rare bleeding disorders. SG-001 is a first-in-class therapy that offers the convenience of monthly dosing, significantly reducing treatment burden while minimizing the risks of thrombosis and inhibitor development,

Seragene Therapeutics is a company in advanced therapies.

Profile

SeraGene has developed SG-001, a universal siRNA-based hemostatic agent aimed at treating a wide range of rare bleeding disorders. SG-001 is a first-in-class therapy that offers the convenience of monthly dosing, significantly reducing treatment burden while minimizing the risks of thrombosis and inhibitor development, making it a safer and more effective alternative to current options. […]

The company sits in the advanced therapies segment, where it competes on its core product or service.

Its current recorded stage is Creative Destruction Lab alumni company.

Website: seragenetx.com